XIFAXAN—unconventionally active in the gut
This information is intended for U.S. residents only.
Stops travelers’ diarrhea
XIFAXAN® is indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli.
E. coli is the most common cause of travelers’ diarrhea in Latin America, the Caribbean, and Africa.1
XIFAXAN works in a unique way to effectively treat travelers’ diarrhea in 79.2% of patients.2*
Minimal impact on gut flora
XIFAXAN targets pathogenic E. coli without causing long-term changes to gut flora balance.3
Halts overgrowth without overkill
XIFAXAN inhibits organism reproduction and may alter virulence of E. coli.2
Offers an established safety profile
XIFAXAN offers no clinically relevant resistance when used as directed,4 and has a low risk of drug-drug interactions.
XIFAXAN has 20+ years of global experience and more than 500 clinical citations.4
Easy administration
XIFAXAN tablets can be taken orally with or without food.
The recommended dose for travelers' diarrhea is one 200 mg tablet taken 3 times a day for 3 days.
*In a randomized, double-blind, placebo-controlled study conducted in Mexico, Guatemala, and Kenya, the efficacy of XIFAXAN (200 mg orally 3 times a day for 3 days) was evaluated in 254 adult subjects with travelers' diarrhea. Stool specimens were collected before treatment and 1 to 3 days following the end of treatment to identify enteric pathogens, predominantly Escherichia coli. The clinical efficacy of XIFAXAN was assessed by the time to return to normal, formed stools and resolution of symptoms.
References
1. Yates J. Traveler’s diarrhea. Am Fam Physician. 2005;71:2095-2100.
2. Huang DB, DuPont HL. Rifaximin—a novel antimicrobial for enteric infections. J Infect. 2005;50(2):97-106.
3. De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res. 1986;12:979-981.
4. Data on file, Salix Pharmaceuticals, Inc.
SAFETY CONSIDERATIONS
Xifaxan® (rifaximin) Tablets are indicated for the treatment of patients (≥12 years of age) with travelers’ diarrhea caused by noninvasive strains of
Escherichia coli. Xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. Xifaxan should be
discontinued if diarrhea symptoms get worse or persist more than 24-48 hours and alternative antibiotic therapy should be considered. Escherichia coli has been shown to develop resistance to rifaximin in vitro. However, the clinical significance of such an effect has not been studied.
In clinical trials, Xifaxan was generally well tolerated. The most common side effects (vs. placebo) were flatulence 11.3% (vs. 19.7%), headache 9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1%), rectal tenesmus 7.2%
(vs. 8.8%), defecation urgency 5.9% (vs. 9.2%) and nausea 5.3% (vs. 8.3%).
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: